Early epoetin treatment in patients with renal insufficiency

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 3, 2000, Pages 40-44

  Ritz, Eberhard ^a   Eisenhardt, Antje ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anaemia; Blood pressure control; Disease progression; Epoetin; Glomerular filtration rate; Left ventricular hypertrophy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CAPTOPRIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; COGNITION; CONTROLLED STUDY; DIALYSIS; DISEASE COURSE; EXERCISE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEPHROLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; RETROSPECTIVE STUDY; SEXUAL FUNCTION;

EID: 0033824521     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027976     Document Type: Article

References (32)

1. Serum erythropoeitin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function
2. Characterization of the anemia of chronic renal failure and the mode of its correction by a preparation of human erythropoeitin (r-HuEPO). An investigation of the pharmaco-kinetics of intravenous erythropoeitin and erythro-kinetics
3. Angiotensin II increases erythropoietin production in healthy human volunteers
4. Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993
5. Hematocrit level and associated mortality in hemodialysis patients
6. Clinical and echocardiographic disease in patients starting end stage renal disease therapy
7. Optimal haemoglobin during treatment with recombinant human erythropoietin
8. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass
9. Effects of hematocrit on renal hemodynamics and sodium excretion in hydropenic and volume-expanded dogs
10. Dynamics of glomerular filtration in the rat. VIII. Effects of hematocrit
11. Renal haemodynamics in primary polycythaemia
12. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model
13. Prevention of accelerated progression of renal failure induced by recombinant human erythropoietin in the rat remnant kidney
14. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in pre-dialysis patients
15. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients
16. Effect of recombinant human erythropoietin on renal function in humans
17. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients
18. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients
19. Evidence for renal vasodilatation in pre-dialysis patients during correction of anemia by erythropoietin
20. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
21. Renal function in predialysis children with chronic renal failure treated with EPO
22. Effect of recombinant erythropoietin therapy on the rate of progression of chronic renal failure (CRF)
23. Recombinant human erythropoietin treatment in predialysis patients. A double-blind placebo-controlled trial
24. Effects of exercise training in predialytic uremic patients
25. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
26. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients
27. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure
28. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
29. How should anemia be managed in pre-dialysis patients?
30. Impact of left ventricular hypertrophy on survival in end stage renal disease